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Abstract. Chloroquine combined with primaquine was evaluated for therapy of uncomplicated malaria caused by
Plasmodium falciparum in nonimmune Javanese migrants to northeastern Papua, Indonesia. Subjects were randomized
to treatment with standard chloroquine therapy (25 mg/kg in 3 doses over the course of 48 hours) with 30 mg primaquine
administered daily for 28 days (n  25) or a placebo of primaquine (n  28). The 14-day cumulative incidence of
therapeutic failure was 56% with primaquine and 79% with placebo (odds ratio [OR], 0.35; 95% confidence interval
[CI], 0.1–1.3; P  0.08). Primaquine administered daily created a marginally significant improvement in therapeutic
efficacy at day 14, but not at day 7 (20% versus 36%; OR, 0.2; 95% CI, 0.1–1.8; P  0.2) or day 28 (82% versus 93%;
OR, 0.31; 95% CI, 0.04–2.1; P  0.23). This report corroborates studies suggesting that therapeutic doses of primaquine
exert no discernible effect on parasitemia by P. falciparum.
INTRODUCTION
Chloroquine and primaquine remain in common use
against uncomplicated malaria in the developing world. Chlo-
roquine still constitutes first-line therapy for infection by
Plasmodium falciparum for most people exposed to risk in
Asia—for example, in India, the Philippines, and Indonesia.
Primaquine, which is typically used for the prevention of re-
lapse by Plasmodium vivax (15 mg daily for 14 days), is also
widely used in Asia against P. falciparum as a single 45-mg
gametocytocidal dose. Although therapeutic regimens of pri-
maquine exert curative activity against blood stages of P.
vivax organisms,1,2 most evidence suggests primaquine has no
effect on blood stages of P. falciparum.3–5 This may bear on
the finding of apparently distinct mechanisms of resistance to
chloroquine by these 2 species.6
In July 1992 (Arso VIII) and June 1993 (Arso XI), we
enrolled subjects in a randomized, blinded, placebo-con-
trolled trial of a primaquine adjunct to standard chloroquine
therapy. The findings with P. vivax have been published else-
where in a report that details the conduct of the studies.2 In
brief, 53 subjects (nonimmune Javanese migrants) with un-
complicated malaria caused by P. falciparum provided in-
formed consent and were randomized to receive standard
chloroquine therapy (Resochin; P. T. Bayer Indonesia,
Jakarta, Indonesia; provided as uncoated scored tablets; 10 +
10 + 5 mg/kg at 24-hour intervals) with primaquine (generic
label, Sanofi-Winthrop, New York, NY, as coated unscored
tablets containing 15 mg base, 0.5 mg/kg daily for 28 days) or
a nonidentical placebo (identical to generic primaquine from
Kimia Farma, Bandung, as an uncoated, scored tablet con-
taining starch and amylose). Subjects were at least 6 years old
and had at least 40 asexual parasites per microliter of blood;
in addition, they tested negative for glucose-6-phosphate de-
hydrogenase deficiency (NADP+ spot test; Sigma Chemical
Co., St. Louis, MO). The mean age of the 53 subjects was 23
years (range, 6–40 years), and most were men (n  45). The
geometric mean density of asexual parasites was 2,744/L. No
significant differences in these parameters appeared between
the primaquine and placebo groups.
Therapy was directly observed beginning on day 0 of the
evaluation and ending with the last dose of primaquine on day
28. Blood films were collected, stained with Giemsa reagents,
and read microscopically on days 0, 1, 2, 4, 7, 11, 18, 21, 25,
and 28, or at any time a subject complained of illness. Figure
1 illustrates the cumulative incidence of therapeutic failure
(persistent or recurrent asexual parasitemia) for both treat-
ment groups estimated by life-table analysis. No significant
differences in risk of therapeutic failure occurred between the
primaquine and placebo groups. A marginally significant dif-
ference appeared only at day 14 (56% versus 79%; odds ratio,
0.35; 95% confidence interval, 0.4–1.3; P  0.08). Daily doses
of 0.5 mg/kg primaquine over the 28 days of follow-up exerted
FIGURE 1. Cumulative incidence of recurrent asexual parasitemia
by Plasmodium falciparum after chloroquine therapy combined with
30 mg daily primaquine (dashed line) or a placebo (solid line).
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no discernible effect on the clearance and recurrence of
asexual parasitemia by P. falciparum.
Our findings corroborate others suggesting that therapeutic
doses of primaquine exert no effect on asexual parasitemia by
P. falciparum, despite an apparently profound effect against
asexual blood forms of P. vivax shown in other studies1 and in
parallel2 with the findings reported here. These findings also
corroborate the very high risk of therapeutic failure with chlo-
roquine monotherapy against P. falciparum acquired in
northeastern Papua, Indonesia.7–9
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